Breast Cancer Molecular Subtypes Among Moroccan Women


Breast Cancer
Molecular Classification


How to Cite

Mahir W, Rouas L, Ferhati D, Rhrab B, Alhamany Z, Cherradi N. Breast Cancer Molecular Subtypes Among Moroccan Women. Integr J Med Sci [Internet]. 2016 Jan. 30 [cited 2024 Jul. 24];3:47-54. Available from:


Introduction: Breast cancer remains despite therapeutic progress, the leading cause of death by cancer among women. It represents a group of very heterogeneous clinical, histopathological and molecular diseases. Molecular heterogeneity has been demonstrated by genomic analysis, even for similar histology cancers. Four subgroups of breast carcinomas are distinguished: Luminal A, Luminal B, HER2 overexpression, and Basal-like. The Immuno-histo-chemical analysis uses ip (estrogen receptors) RE, the PR (progesterone receptors), the ((Human Epidermal Growth Factor Receptor-2), the Ki67 (proliferation marker) HER2, CK5/6) has shown a subdivision into subgroups similar to those found by genomic analysis. These subgroups are different from the point of view of clinical course and response to adjuvant treatment.
Objectives: The aim of this work is to study the molecular profile of breast cancers by immunostaining on Moroccan series to a classification with a prognostic value allowing a treatment tailored to each group of patients. Furthermore, the molecular subgroups were correlated to other clinical and histological factors.
Material and methods: It is a prospective study of the laboratory of Anatomy and Pathologic cytology of the children's Hospital, the service I of the maternity hospital in Rabat, and in cooperation with the United Nations Centre of pathological anatomy. To do this, 88 cases of breast cancer together were diagnosed between January 1, 2010, and December 31, 2014, taking a period of five years. All tissue samples made a subject study of Immuno-histo-chemistry with the following markers: RE, PR, HER2, and Ki67. Only negative triple cases (HR and HER2 negative) benefited from an additional marking with CK5/6 and EGFR to set the basal profile.
Results: Series of 88 cases of mammary carcinomas observed on operating parts, ranged in age between 28 and 84 years old, with an average of 51 ± 12, 8. Carcinoma infiltrating non-specific (DOCTORS) was the most frequent (87.5%). Ranks histo-prognostic Scarff Bloom and Richardson (SBR) 2 and 3 respectively accounted for 45.5 and 51.1% of cases and only 2, 3% of the DOCTORS were grade 1. Luminal B (53.4%) was under the most common molecular group, followed by Luminal A (23.9%), HER2 + (15.9%), and triple-negative (6.8%). The correlation of molecular type of tumors with different prognostic factors showed only one significant connection with the SBR grade.


Lorca PF, Dauplat MH. Les signatures moléculaires des cancers du sein : le point de vue du pathologiste, Rev Franco Lab. 2011 Jan ; 2011(428) : 43-47.

Mathieu MC. Les sous-types moléculaires des cancers du sein. La Lettre du Sénologue n ° 38. Oct Nov Déc 2007. Pp 33-34.

Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000 Aug 17; 406(6797):747-52.

Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki-67 Index, Her2 status, and prognosis of patients with luminal B breast cancer. J Nat Cancer Inst. 2009 May 20; 101(10):736–750.

Viani GA, Afonso SL, Stefano EJ, De Fendi IL, Soares VF. Adjuvant trastuzumab in the treatment of her 2 positive early breast cancer: A meta analysis of published randomized trials. BMC Cancer. 2007 Aug 8; 7:153.

Soerjomataram I, Louwman MW, Ribot JG, Roukema JA, Coebergh JW. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat 2008 Feb; 107:309-30.

Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genom. 2006 Apr 27; 7:96.

Abbass Fouad, Akasbi Yousra, Znati Kaoutar, El Mesbahi Omar, Amarti Afaf, et Bennis Sanae. Classification moléculaire du cancer du sein au Maroc. Pan Afr Med J. 2012; 13: 91. [Accessed 16 June 2021]. Available From:

Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. Jama. 2006 Jun 7;295(21):2492–2502.

Hugh J, Hanson J, Cheang MC, Nielsen TO, Perou CM, Dumontet C, et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 Trial. J Clin Oncol. 2009 Mar 10; 27(8):1168–76.

Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004 Aug 15; 10(16):5367–74.

Weigelt B, Geyer FC, Natrajan R, Lopez-Garcia MA, Ahmad AS, Savage K, et al. The molecular underpinning of lobular histological growth pattern: a genome-wide transcriptomic analysis of invasive ductal carcinomas of no special type. J Pathol 2010;220(1):45-57.

Van’t Veer LJ, Dai H, van de Vijver MJ, He DY, Hart AA, Mao M et al. Gene expression profling predicts clinical outcome of breast cancer. Nature 2002 Jan 31;415(6871):530-6.

de Vijver MJ, He Y, Van’t Veer LJ, Dai H, Hart AA, Voskuil WD, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002 Dec 19; 347(25):1999-2009.

Bechr Hamrita, Ben Nasr H, Hammann P, Kuhn L, Ben Anes A, Dimassi S, et Al. Pour une meilleure compréhension de la physiopathologie des cancers mammaires : l’approche protéomique. Ann Biol Clin (Paris). 2012 Oct 1; 70(5):553-565.

Khan A, Ian Ol, Andrew MH, Cosar EF, Rakha AE, Kandil D. Precision Molecular Pathology of Breast Cancer. New York: Springer; 2015.

Chuthapisith S, Permsapaya W, Warnnissorn M, Akewanlop C, Sirivatanauksorn V, Prasarttong Osoth P . Breast cancer subtypes identified by the ER, PR and Her-2 status in Thai women. Asian Pac J Cancer Prev. 2012; 13(2), 459-62.

Kadivar M, Mafi N, Joulaee A, Shamshiri A, Hosseini N. Breast cancer molecular subtypes and association with clinicopathological characteristics in Iranian women, 2002-2011. Asian Pac J Cancer Prev. 2012, 13(5):1881-6.

Abalkail AA, Zahawi HM, Almasri NM, Hameed OK. The role of young population structure in determining age distribution of breast cancer in Jordan. J Bahrain Med Society. 2003; 15: 28-33.

Ontilo AA, Engel J, Greenlee RT, Mukesh B. Breast cancer subtypes based on ER/PR and HER-2/neu expression: Comparison of clinicopathologic features and survival. Clin Med Res. 2008 ; 7 : 4-13.

Camille Franchet, Raphaëlle Duprez-Paumier, Magali Lacroix-Trik. Cancer du sein luminal et apport des classifications intrinsèques moléculaires : comment identifier les tumeurs luminales A et B en 2015?. Bull Cancer. 2015 Jun; 102 (6 Suppl 1): S34–S46.

Najafi B, Anvari S, Roshan ZA. Disease free survival among molecular subtypes of early stage breast cancer between 2001 and 2002 in Iran. Asian Pac J Cancer Prev. 2013; 14(10) 5811-16.

Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independant gene expression data sets. Proc Natl Acad Sci U S A 2003 Jul 8; 100(14):8418-23.

Milikan RC, Newman B, Tse CK, Moorman G, Conway K, Dressler GL, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008 May; 109 (1):123-39.

Jia WJ, Jia HX, Feng HY, Yang YP, Chen K , Su XF. Her-2 enriched tumors have the highest risk of local recurrence in Chinese patients treated with breast conservation therapy. Asian Pac J Cancer Prev. 2014;15: 315-20.

Su Y, Zheng Y, Zheng W, Gu K,Chen Z, Li G, et al. Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study. BMC Cancer. 2011 Jul 12; 11, 292.

El-Hawary AK, Abbas AS, Elsyayed AA, Zalata KR . Molecular subtypes of breast carcinoma in Egyptian women: Clinicopathological features. Pathol Res Pract. 2012 Jul 15; 208(7) :382-6.

Kumar N, Patni P, Agarwal A, Khan MA, Parashar N. Prevalence of molecular subtypes of invasive breast cancer: A retrospective study. Med J Armed forces india.2015 Jul; 71(3) 254-258.

Kurebayashi J, Moriya T, Ishida T, Hirakawa H, Kurosumi M, Akiyama F, et al. the prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. The Breast. 2007 Dec; 16 Suppl 2: S72-S77.

Fernandes RC, Bevilacqua JL, Soares IC, Siqueira SA, Pires L, Hegg R, et al. Coordinated expression of ER, PR and HER-2 define different prognostic subtypes among poorly differentiated breast carcinomas. Histopathology. 2009 Sep;55(3):346-352.

Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013 Sep;24(9):2206–23.

Ward S, Pilgrim H, Hind D. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal. Health Technol Assess. 2009 Jun ;13(Suppl 1):1–6.

Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value thantriple-negative phenotype. Clin Cancer Res. 2008 Mar 1; 14(5):1368–76.

Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006 Feb; 19(2):264–71.

Hamrita B, Ben Nasr H, Hammann P, Kuhn L, Ben Anes A, Dimassi S, et al. Pour une meilleure compréhension de la physiopathologie des cancers mammaires : l’approche protéomique. Ann Biol Clin (Paris) 2012 Oct 1 ; 70(5) : 553-65.

Calza S, Hall P, Auer G, Bjöhle J, Klaar S, Kronenwett U, et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res. 2006;8(4):R34.

Jumppanen M, Gruvberger-Saal S, Kauraniemi P, Tanner M, Bendahel PO, Lundin M, et al. Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res. 2007; 9:R16.

Fulford LG, Reis-Filho JS, Ryder K, Jones C, Gillet CE, Hanby A, et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res. 2007; 9(1):R4.

Siziopikou KP, Cobleigh M. The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. Breast. 2007 Feb; 16(1):104 – 107.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2016 Wissal Mahir et al.


Download data is not yet available.


Metrics Loading ...